Unknown

Dataset Information

0

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.


ABSTRACT:

Objective

The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trials is poorly defined.

Study design

This retrospective observational study of clinical data from Belgium and Portugal evaluates genotypic information from HIV-1 drug-naive patients obtained for the purpose of drug resistance testing. Rilpivirine resistance-associated mutations (RPV-RAMs) were defined based on clinical trials, phenotypic studies, and expert-based resistance algorithms. Viral susceptibility to RPV alone and to the single-tablet regimen was estimated using expert-based resistance algorithms.

Results

In 4,631 HIV-1 treatment-naive patients infected with diverse HIV-1 subtypes, major RPV-RAMs were detected in 4.6%, while complete viral susceptibility to RPV was estimated in 95% of patients. Subtype C- and F1-infected patients displayed the highest levels of reduced viral susceptibility at baseline, respectively 13.2% and 9.3%, mainly due to subtype- and geographic-dependent occurrence of RPV-RAMs E138A and A98G as natural polymorphisms. Strikingly, a founder effect in Portugal resulted in a 138A prevalence of 13.2% in local subtype C-infected treatment-naive patients. The presence of transmitted drug resistance did not impact our estimates.

Conclusion

RPV is the first HIV-1 inhibitor for which, in the absence of transmitted drug resistance, intermediate or high-level genotypic resistance can be detected in treatment-naive patients. The extent of RPV susceptibility in treatment-naive patients differs depending on the HIV-1 subtype and dynamics of local compartmentalized epidemics. The highest prevalence of reduced susceptibility was found to be 15.7% in Portuguese subtype C-infected treatment-naive patients. In this context, even in the absence of transmitted HIV-1 drug resistance (TDR), drug resistance testing at baseline should be considered extremely important before starting treatment with this NNRTI.

SUBMITTER: Theys K 

PROVIDER: S-EPMC4845676 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Theys Kristof K   Van Laethem Kristel K   Gomes Perpetua P   Baele Guy G   Pineda-Peña Andrea-Clemencia AC   Vandamme Anne-Mieke AM   Camacho Ricardo J RJ   Abecasis Ana B AB  

AIDS research and human retroviruses 20160129 5


<h4>Objective</h4>The latest nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) is indicated for human immunodeficiency virus type-1 (HIV-1) patients initiating antiretroviral treatment, but the extent of genotypic RPV resistance in treatment-naive patients outside clinical trials is poorly defined.<h4>Study design</h4>This retrospective observational study of clinical data from Belgium and Portugal evaluates genotypic information from HIV-1 drug-naive patients obtained for  ...[more]

Similar Datasets

| S-EPMC10990719 | biostudies-literature
| S-EPMC10199109 | biostudies-literature
2010-05-18 | E-GEOD-13253 | biostudies-arrayexpress
| S-EPMC7418974 | biostudies-literature
| S-EPMC3386125 | biostudies-other
| S-EPMC3259890 | biostudies-literature
| S-EPMC7526531 | biostudies-literature
| S-EPMC4710214 | biostudies-literature
| S-EPMC2785855 | biostudies-literature
| S-EPMC5176287 | biostudies-literature